Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK202 for Injection in Combination With Drugs in NSCLC Participants.

Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
This article has no abstract
Epistemonikos ID: e713b28c8672b8a3f1be1757bce3f880e9c144d6
First added on: May 23, 2026